Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]
In development [GID-TA10711] Expected publication date: 15 September 2021
Search results
523 results
-
-
Bimekizumab for treating moderate to severe chronic plaque psoriasis [ID2692]
In development [GID-TA10649] Expected publication date: 22 September 2021
-
Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care
In development [GID-DT28] Expected publication date: TBC
-
Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis
In development [GID-DT9] Expected publication date: TBC
-
KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)
In development [GID-DT14] Expected publication date: TBC
-
The Assurance Nasal Alar SpO2 Sensor (discontinued)
In development [GID-MT510] Expected publication date: TBC
-
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)
In development [GID-MT517] Expected publication date: TBC
-
DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)
In development [GID-MT536] Expected publication date: TBC
-
Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)
In development [GID-MT130] Expected publication date: TBC
-
Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)
In development [GID-MT163] Expected publication date: TBC
-
Microthane implants for breast reconstruction or breast augmentation (discontinued)
In development [GID-MT267] Expected publication date: TBC
-
SILK artery reconstruction device (discontinued)
In development [GID-MT81] Expected publication date: TBC
-
SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)
In development [GID-MT516] Expected publication date: TBC
-
OraQuick® HCV Rapid Antibody Test (discontinued)
In development [GID-MT117] Expected publication date: TBC
-
Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610
In development [GID-TA10499] Expected publication date: TBC
-
Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]
In development [GID-TA10416] Expected publication date: TBC
-
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169
In development [GID-TA10324] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335
In development [GID-TA10315] Expected publication date: TBC
-
Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455
In development [GID-TA10356] Expected publication date: TBC
-
Prostate cancer (prevention) - dutasteride [ID75]
In development [GID-TAG409] Expected publication date: TBC
-
Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]
In development [GID-TAG411] Expected publication date: TBC
-
Obesity - lorcaserin [ID337]
In development [GID-TAG420] Expected publication date: TBC
-
Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]
In development [GID-TAG369] Expected publication date: TBC
-
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305
In development [GID-TA10244] Expected publication date: TBC
-
Durvalumab in combination for untreated extensive stage small-cell lung cancer [ID1618]
In development [GID-TA10493] Expected publication date: TBC
-
Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]
In development [GID-TA10314] Expected publication date: TBC
-
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357
In development [GID-TA10322] Expected publication date: TBC
-
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
In development [GID-TA10555] Expected publication date: TBC
-
Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]
In development [GID-TA10474] Expected publication date: TBC
-
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development [GID-TA10592] Expected publication date: TBC
-
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]
In development [GID-TA10780] Expected publication date: TBC
-
Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (CDF review of TA620) [ID3788]
In development [GID-TA10712] Expected publication date: TBC
-
Vericiguat for treating chronic heart failure with reduced ejection fraction [ID2731]
In development [GID-TA10595] Expected publication date: TBC
-
Pembrolizumab for advanced, unresectable or metastatic urothelial cancer (CDF review of TA522) [ID1634]
In development [GID-TA10710] Expected publication date: TBC
-
Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]
In development [GID-TAG432] Expected publication date: TBC
-
Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]
In development [GID-TAG403] Expected publication date: TBC
-
Obesity - phentermine (with topiramate) [ID543]
In development [GID-TAG439] Expected publication date: TBC
-
Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]
In development [GID-TAG372] Expected publication date: TBC
-
Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]
In development [GID-TAG423] Expected publication date: TBC
-
Prostate cancer - intensity modulated radiotherapy [ID17]
In development [GID-TAG396] Expected publication date: TBC
-
Colon cancer (adjuvant) - irinotecan [ID379]
In development [GID-TAG380] Expected publication date: TBC
-
Head and neck cancer - contusugene ladenovec [ID76]
In development [GID-TAG407] Expected publication date: TBC
-
Lung cancer (non-small cell) - afatinib [ID357]
In development [GID-TAG422] Expected publication date: TBC
-
Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]
In development [GID-TAG330] Expected publication date: TBC
-
Prostate cancer (hormone refractory) - atrasentan [ID390]
In development [GID-TAG379] Expected publication date: TBC
-
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
In development [GID-TAG300] Expected publication date: TBC
-
Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]
In development [GID-TAG440] Expected publication date: TBC
-
Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]
In development [GID-TAG410] Expected publication date: TBC
-
Clostridium difficile associated diarrhoea - tolevamer [ID378]
In development [GID-TAG389] Expected publication date: TBC
-
Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46]
In development [GID-TAG405] Expected publication date: TBC